• MARTIN Kennedy’s letter on the trans issue (Use of puberty blockers will result in litigation, August 11) has hit the nail on the head by highlighting that these drugs were previously only given to male sex-offenders.

Drug companies constantly seek secondary markets for their products and there is a lucrative opportunity to peddle these as a solution to the natural discomfort synonymous with puberty.

Unfortunately, as we learned in the High Court case against the Tavistock, puberty blockers don’t just limit sexual development but also bone development, resulting in cases of osteoporosis and joint problems, blood disorders, depression, impaired IQ, and memory.

Puberty is hard, but essentially it is in navigating puberty that we grow. Puberty blockers inhibit the mental and emotional maturation processes too. It’s not a good solution for kids identifying as trans.

For boys, an immature penis isn’t big enough to later be inverted into a viable neo-vagina. For girls, they may be able to have hysterectomies and later grow beards but, like my friend, their skeletal frame remains the size of a child.

Puberty blockers aren’t the golden pill they are marketed as and if anyone still believes they are necessary to prevent the threat of suicide I suggest they check out statsforgender.org which just blows this myth right out of the water.

Mr Kennedy’s prediction of unprecedented litigation over their use is timely, with a 1,000-case class action being announced by law firm Pogust Goodhead only this week. Gender-dysphoric teens need better mental health care, not sterilising drugs.

Angela Mason’s letter is ironic in calling for “a more informed debate” on the trans issue when she confuses beta-blockers with puberty blockers. Keep taking the beta-blockers – they’re all right.

NAME AND ADDRESS SUPPLIED, WC1